Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × BI 2536 × Clear all
NCT00412880 2022-06-22

BI 2536 Second Line Monotherapy in SCLC

Boehringer Ingelheim

Phase 2 Completed
23 enrolled 10 charts

Carcinoma, Small Cell

NCT00376623 2022-06-21

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

Boehringer Ingelheim

Phase 2 Completed
96 enrolled 26 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00710710 2022-05-04

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Boehringer Ingelheim

Phase 2 Completed
89 enrolled 20 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡